{"nctId":"NCT01241240","briefTitle":"Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension","startDateStruct":{"date":"2011-03"},"conditions":["Glaucoma, Open-Angle","Ocular Hypertension"],"count":192,"armGroups":[{"label":"Triple Combination Therapy","type":"EXPERIMENTAL","interventionNames":["Drug: bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)"]},{"label":"Combigan®","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution"]}],"interventions":[{"name":"bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)","otherNames":[]},{"name":"Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution","otherNames":["COMBIGAN®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Ocular hypertension or primary open-angle glaucoma in each eye\n* Requires treatment with IOP-lowering medication in both eyes\n\nExclusion Criteria:\n\n* Required chronic use of ocular medications during the study other than study medication\n* Use of any corticosteroids within 30 days\n* History of any prior eye surgery, except for uncomplicated eye surgery performed more than 6 months before the Screening visit\n* Anticipated wearing of contact lenses during the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) at Week 12","description":"IOP is a measurement of the fluid pressure inside the eye. For each eye, the IOP was either the average of 2 measurements, or, if a third measurement was required, the median of the 3 measurements. The worse eye was determined based on the IOP results at Baseline. The mean worse eye IOP was the average of the IOP measurements of the worse eye at hours 0 and 2 at week 12. A negative change from Baseline indicated improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.62","spread":"2.475"},{"groupId":"OG001","value":"25.12","spread":"2.178"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.03","spread":"2.661"},{"groupId":"OG001","value":"-9.18","spread":"2.566"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean Worse Eye IOP","description":"IOP is a measurement of the fluid pressure inside the eye. For each eye, the IOP was either the average of 2 measurements, or, if a third measurement was required, the median of the 3 measurements. The worse eye was determined based on the IOP results at Baseline. The mean worse eye IOP was the average of the IOP measurements of the worse eye at hours 0 and 2 at each visit. A negative change from Baseline indicated improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.62","spread":"2.475"},{"groupId":"OG001","value":"25.12","spread":"2.178"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.18","spread":"3.149"},{"groupId":"OG001","value":"-8.90","spread":"3.044"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.40","spread":"2.802"},{"groupId":"OG001","value":"-9.06","spread":"2.925"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.06","spread":"2.793"},{"groupId":"OG001","value":"-9.21","spread":"2.306"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.77","spread":"2.852"},{"groupId":"OG001","value":"-9.02","spread":"2.869"}]}]}]},{"type":"SECONDARY","title":"Mean Worse Eye IOP","description":"IOP is a measurement of the fluid pressure inside the eye. For each eye, the IOP was either the average of 2 measurements, or, if a third measurement was required, the median of the 3 measurements. The worse eye was determined based on the IOP results at Baseline. The mean worse eye IOP was the average of the IOP measurements of the worse eye at hours 0 and 2 at each time-point.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.43","spread":"2.785"},{"groupId":"OG001","value":"16.23","spread":"2.968"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.05","spread":"2.634"},{"groupId":"OG001","value":"16.08","spread":"2.726"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.38","spread":"2.587"},{"groupId":"OG001","value":"15.96","spread":"2.705"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.68","spread":"2.709"},{"groupId":"OG001","value":"16.11","spread":"2.935"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.43","spread":"2.344"},{"groupId":"OG001","value":"15.92","spread":"2.867"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":93},"commonTop":["Conjunctival hyperaemia","Eye irritation","Somnolence","Dry eye","Visual field defect"]}}}